We've been writing for the IPKat blog. Here are some of our recent posts on that blog:
The New USPTO Interim Guidance on Patent Subject Matter Eligibility
This post briefly describes the latest guidance based on the Mayo, Myriad and Alice cases, giving a brief history of how 'eligibility' has evolved from the Bilski case onwards.
China's IP journey: from 'bad guys' to 'good guys' to patent superpower
A brief history of how China's patent system developed, often in line with its own interests, and what other countries might learn from it.
Forsgren's SPC; what does the marketing authorisation have to say about the active ingredient
This reviews a recent decision on an SPC from the CJEU, and places it in the context of SPC case law.
Biotech financing: the risk components, 'going long' and patents as knowledge currency
A review of the early stage financing landscape in the area of therapeutics and how collaborations and ecosystems are becoming increasingly important, thus changing the way that patents are used.
